Abstract: Compositions containing depolymerized fucane sulphates characterized by the following parameters (percentages by weight on the dry product): Molecular weight: 5,000-30,000 dalton; Sulphur: 5-16%; Fucose: 25-60%; Uronic acids 2-25%; they increase the percentage of growing hair and inhibit the Pytirosporun growth on the skin.

Abstract: Fucans with low molecular weight having anticoagulant, antithrombinic and antithrombotic activity.Fucan sulfates having molecular weight between 14000 and 29000 Dalton show a remarkable anticoagulant activity both in the global coagulation mechanism (APTT) and in the last phase of coagulation (antithrombinic activity). These compounds are useful also as antithrombotic drugs.

Abstract: Cathepsin G-inhibiting aptamers comprising oligonucleotides selected from the group consisting of the consensus sequences: ##STR1## wherein N represents nucleotides and the figures represent the number of possible nucleotides at that site; said cathepsin G-inhibiting aptamers are suggested as medicament.

Abstract: The invention discloses new compositions of mesalazine in the form of aqueous suspensions, characterized in that they are more stable than those of the prior art. The compositions contain colloidal cellulose and one or more hydrophilic thickening agents.

Abstract: A pharmaceutical composition comprising a polydeoxyribonucleotide of random sequence formula is disclosed, andP.sub.v, (dAp).sub.w, (dGp).sub.x, (dTp).sub.y, (dCp).sub.zwhereinP.sub.v is 1-5 phosphoric radicals,(dAp).sub.w is 12-24 deoxyadenylic monomers,(dGp).sub.x is 10-20 deoxyguanylic monomers,(dTp).sub.y is 13-26 deoxythymidylic monomers, and(dCp).sub.z is 10-20 deoxycytidylic monomers;wherein the polydeoxyribonucleotide has:a homogenous anodic mobility in electrophoresis,an extinction coefficient E.sup.1%.sub.1 cm at 260.+-.1 nm=220.+-.10,an extinction coefficient E.sub.230 /E.sub.260 =0.45.+-.0.04,a molar extinction coefficient (referred to phosphorous), .epsilon.(P)=7750.+-.500,a rotary power ?.alpha.!.sup.20.degree..sub.D =53.degree..+-.6, anda reversible hyperchromicity as percent in native DNA h=15.+-.5, in combination with a pharmaceutically acceptable carrier or diluent. A method of treating or preventing a diabetic neuropathy using the polydeoxyribonucleotide is also shown.

Abstract: The invention discloses new oligodeoxyribonucleotides of animal origin, having a molecular weight comprised between 4000 and 10000 daltons, that can be obtained by fractionation of polydeoxyribonucleotides or otherwise by chemical or enzymatic depolymerization of high molecular weight deoxyribonucleic acids. The new compounds are endowed with a significant anti-ischemic activity.

Abstract: There are provided oligodeoxyribonucleotides of animal origin, having a molecular weight between 4000 and 10000 daltons, that can be obtained by fractionation of polydeoxyribonucleotides or otherwise by chemical or enzymatic depolymerization of high molecular weight deoxyribonucleic acids. The compounds are endowed with a significant anti-ischemic activity.

Abstract: Depolymerization of stabilized solutions of highly polymerized and nicked polydeoxyribonucleotides, as obtained through stabilizing aggregation of raw nucleic acids, the depolymerization being carried out by heating at controlled temperature and being controlled as a function of the variation of the reversible hyperchromicity, followed by the removal of the hydrogen bonds in the double stranded filaments and by thermal stabilization of the single stranded filaments, polydeoxyribonucleotide is obtained. The polydeoxyribonucleotide has the following formula of random sequence:P.sub.1-5, (dAp).sub.12-24, (dGp).sub.10-20, (dTp).sub.13-26, (dCp).sub.10-20,whereinP=phosphoric radicaldAp=deoxyadenylic monomerdGp=deoxyguanylic monomerdTp=deoxythymidylic monomerdCp=deoxycytidylic monomerand has well defined chemico-physical properties, reproducible in industrial production.

Abstract: Compositions for topical use containing as active ingredients depolymerized deoxyribonucleic acids can be used for the reduction of the unaesthetisms of the face skin, due to the couperose. Said compositions can be advantageously used also to locally reduce, in the lower limbs, the skin unaesthetisms (dilated capillaries, oedemas, tumefactions), resulting from a situation of an extended physical stress acting on the above-mentioned legs.

Abstract: Pharmaecutical composition for topical use containing Defibrotide have been found effective in the therapy of local pathologies characterized by a reduced resistance of the blood capillary vessels.

Abstract: By ultrafiltration of an aqueous solution wherein there have been formerly dissolved alfa-cyclodextrin and a raw lipidic mixture, the latter characterized in that it contains monosialoganglioside (GM1) either as the sole ganglioside or otherwise in a prevailing quantity over the other associated gangliosides, and after the removal of cyclodextrin at the end of the process, it is obtained GM1 with a titer of at least 95%. The present invention concerns also the intermediate complex that it is being formed between the hereabove said monosialoganglioside and alfa-cyclodextrin.

Abstract: The oral administration to an animal of sulglycotide `(a sulfoglycopeptide)` together with methylcellulose, pectin or tragacanth gum protects the animal against gastric ulcer.

Abstract: A cosmetic preparation is described as comprising at least an effective amount of a nutrient medium for the in vitro culture of isolated human epithelial cells and a related amount of serum of bovine fetus. The preparation is particularly active as a revitalizing agent for the skin, as an anti-wrinkle agent and as a factor for enhancing hair growth. The activity of the aforesaid nutrient medium can be furthermore enhanced by adding extractive mixtures, obtained from the connective tissues of animal organs, mainly mucopolysaccharides.

Abstract: Novel derivatives are disclosed as obtained from chondroitin sulfate, dermatan sulfate and hyaluronic acid, having a molar ratio between sulfate groups and carboxylic groups like that of heparin and furthermore characterized by possessing, as the heparin, the sulfoamino group at the carbon atom at the 6 position of hexosamine.The novel compounds show a very remarkable clearing activity in comparison with the starting mucopolysaccharides, this activity being similar and for some derivatives comparable with that of heparin.Moreover, differently from what normally happens upon sulfating the sulfomucopolysaccharides, the anticoagulating activity of the novel compounds is negligible or anyhow very reduced.The compounds of the present invention find use in the therapy of arteriosclerosis.

Abstract: By carrying out the depolymerization of stabilized solutions of highly polymerized and nicked polydeoxyribonucleotides, as obtained through stabilizing aggregation of raw nucleic acids, the depolymerization being carried out by heating at controlled temperature and being controlled as a function of the variation of the reversible hyperchromicity, followed by the removal of the hydrogen bonds in the double stranded filaments and by thermal stabilization of the single stranded filaments, the polydeoxyribonucleotide, known as Defibrotide is obtained. Defibrotide has the following formula of random sequence:P.sub.1-5,(dAp).sub.12-24,(dGp).sub.10-20, (dTp).sub.13-26,(dCP).sub.10-20,whereinP=phosphoric radicaldAp=deoxyadenylic monomerdGp=deoxyguanylic monomerdTp=deoxythymidylic monomerdCp=deoxycytidylic monomerand has well defined chemico-physical properties, reproducible in the industrial production.

Abstract: A pharmaceutical or dietetic composition for the prevention and treatment of vascular, arteriosclerotic and thrombotic pathologies, comprised of lecithin and oils having a high content of eicosapentaenoic (C 20:5, n-3) and/or docosahexaenoic (C 22:6, n-3) acids, and/or esters thereof.Said composition affords a considerable enhancement of vascular pathologies therapy by the use of natural ingredients commonly employed in human nourishment without any trouble.

Abstract: Defibrotide, a polydeoxyribonucleotide, obtained by extraction from animal organs, is the active ingredient of compositions for the treatment of acute states of myocardial ischemia and infarction.

Abstract: A novel polyaminic resin obtained by crosslinking a polyalkyleneamine (in particular polyethyleneamine) with diisocyanates in solution, is useful as a selective separation or extraction agent of a component having a "complementary" chemical structure (particularly heparin), by means of mere contact or "ionic exchange" with aqueous solutions containing it. Heparin is thus even quantitatively extracted from solutions containing it alone or in mixture with other glucosaminoglycanes. The polyamine can then release the "adsorbed" heparin and be recovered by a treatment with saline solutions. The novel resin is used in pharmaco-biological fields.

Abstract: The invention concerns novel piridoxine derivatives of the general formula: ##STR1## which show anti-inflammatory activity and moreover may show, although not necessarily, also analgesic and/or anti-pyretic activity.

Abstract: The invention concerns novel piridoxine derivatives of the general formula: ##STR1## which show anti-inflammatory activity and moreover may show, although not necessarily, also analgesic and/or anti-pyretic activity.